Published in Proc Natl Acad Sci U S A on November 18, 2008
Heart valve development: regulatory networks in development and disease. Circ Res (2009) 2.41
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest (2011) 1.84
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet (2009) 1.72
MEK Is a Key Regulator of Gliogenesis in the Developing Brain. Neuron (2012) 1.68
MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest (2011) 1.39
Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci U S A (2009) 1.25
Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation. J Clin Invest (2010) 1.21
Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling. Mol Cell Biol (2010) 1.02
Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations. Proc Natl Acad Sci U S A (2009) 1.01
PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? Trends Cardiovasc Med (2011) 1.00
Retracted A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J Biol Chem (2013) 1.00
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature. Proc Natl Acad Sci U S A (2012) 0.98
Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. J Biol Chem (2013) 0.97
Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic response but provokes pathological stress induced cardiac dysfunction. J Mol Cell Cardiol (2014) 0.89
Wnt/β-catenin signaling enables developmental transitions during valvulogenesis. Development (2016) 0.86
Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). BMC Struct Biol (2014) 0.86
RASopathies: unraveling mechanisms with animal models. Dis Model Mech (2015) 0.84
Galnt1 is required for normal heart valve development and cardiac function. PLoS One (2015) 0.81
Protein Kinase A (PKA) Phosphorylation of Shp2 Protein Inhibits Its Phosphatase Activity and Modulates Ligand Specificity. J Biol Chem (2015) 0.79
Raf-mediated cardiac hypertrophy in adult Drosophila. Dis Model Mech (2013) 0.79
Fibroblast-Specific Genetic Manipulation of p38 MAPK in vivo Reveals its Central Regulatory Role in Fibrosis. Circulation (2017) 0.78
SHP-2 deletion in postmigratory neural crest cells results in impaired cardiac sympathetic innervation. Proc Natl Acad Sci U S A (2014) 0.78
The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease. Semin Cell Dev Biol (2014) 0.77
Increased Hemodynamic Load in Early Embryonic Stages Alters Endocardial to Mesenchymal Transition. Front Physiol (2017) 0.77
The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration. J Appl Physiol (1985) (2014) 0.76
The protein tyrosine phosphatase Shp2 is required for the generation of oligodendrocyte progenitor cells and myelination in the mouse telencephalon. J Neurosci (2014) 0.76
Layer specific and general requirements for ERK/MAPK signaling in the developing neocortex. Elife (2016) 0.76
Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines. J Clin Invest (2016) 0.75
The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42. Nat Commun (2016) 0.75
Inhibition of MAPK-Erk pathway in vivo attenuates aortic valve disease processes in Emilin1-deficient mouse model. Physiol Rep (2017) 0.75
Aberrant neuronal activity-induced signaling and gene expression in a mouse model of RASopathy. PLoS Genet (2017) 0.75
The incidence of congenital heart disease. J Am Coll Cardiol (2002) 16.13
Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol (2001) 10.32
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet (2001) 6.96
The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci (2003) 6.24
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet (2003) 5.16
Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A (1997) 4.52
Heart valve development: endothelial cell signaling and differentiation. Circ Res (2004) 4.41
Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science (1999) 3.85
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55
Crystal structure of the tyrosine phosphatase SHP-2. Cell (1998) 3.48
Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child (1968) 3.05
Nf1 has an essential role in endothelial cells. Nat Genet (2002) 2.63
An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep (2003) 2.52
The cardiofaciocutaneous syndrome. J Med Genet (2006) 2.32
Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr (1999) 2.18
Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res (1999) 2.16
Lineage and morphogenetic analysis of the cardiac valves. Circ Res (2004) 2.06
Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos. Dev Dyn (2004) 1.96
Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A (2007) 1.93
MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation (2004) 1.69
Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev Biol (2007) 1.67
Epidemiology of cardiovascular malformations: prevalence and risk factors. Am J Med Genet (2000) 1.65
Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest (2007) 1.48
NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells. J Biol Chem (2002) 1.46
A treadmill exercise regimen for identifying cardiovascular phenotypes in transgenic mice. Am J Physiol (1997) 1.42
Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Mol Cell Biol (2000) 1.38
Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol (1993) 1.30
Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling. Circ Res (2005) 1.06
SHP-2, SH2-containing protein tyrosine phosphatase-2. Int J Biochem Cell Biol (1998) 0.98
Cardiovascular malformations in Turner's and Noonan's syndrome. Br Heart J (1978) 0.90
MAP kinase activation in avian cardiovascular development. Dev Dyn (2004) 0.84
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature (2005) 11.22
Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol (2006) 10.71
Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med (2007) 8.06
Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol (2007) 5.60
Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res (2003) 5.30
Imaging cellular signals in the heart in vivo: Cardiac expression of the high-signal Ca2+ indicator GCaMP2. Proc Natl Acad Sci U S A (2006) 4.71
Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res (2007) 4.53
PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med (2004) 4.50
Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ Res (2006) 4.41
Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med (2008) 3.69
Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem (2007) 3.53
Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res (2003) 3.16
Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest (2007) 3.13
Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation (2008) 2.95
Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun (2004) 2.86
GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res (2006) 2.85
The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res (2006) 2.85
Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation (2005) 2.75
Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res (2005) 2.67
Circadian rhythms govern cardiac repolarization and arrhythmogenesis. Nature (2012) 2.59
Neural crest cells retain multipotential characteristics in the developing valves and label the cardiac conduction system. Circ Res (2006) 2.59
Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice. Proc Natl Acad Sci U S A (2002) 2.56
STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol (2004) 2.53
Mechanisms of necroptosis in T cells. J Exp Med (2011) 2.51
Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med (2008) 2.49
Sarcolipin is a newly identified regulator of muscle-based thermogenesis in mammals. Nat Med (2012) 2.48
Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab (2012) 2.48
A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell (2008) 2.47
Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci U S A (2006) 2.46
Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res (2008) 2.44
Cardiac-specific loss of N-cadherin leads to alteration in connexins with conduction slowing and arrhythmogenesis. Circ Res (2005) 2.44
Induced deletion of the N-cadherin gene in the heart leads to dissolution of the intercalated disc structure. Circ Res (2005) 2.44
Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest (2003) 2.43
FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem (2009) 2.40
Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation (2010) 2.37
Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res (2002) 2.35
Phenotyping hypertrophy: eschew obfuscation. Circ Res (2003) 2.32
A threshold of GATA4 and GATA6 expression is required for cardiovascular development. Proc Natl Acad Sci U S A (2006) 2.32
Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A (2004) 2.32
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol (2002) 2.30
Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin. FASEB J (2007) 2.30
Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem (2004) 2.24
Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J Clin Invest (2007) 2.23
Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation (2010) 2.23
Shigella induces mitochondrial dysfunction and cell death in nonmyleoid cells. Cell Host Microbe (2009) 2.21
Impact of beta-myosin heavy chain expression on cardiac function during stress. J Am Coll Cardiol (2004) 2.17
Genetic variability in forced and voluntary endurance exercise performance in seven inbred mouse strains. J Appl Physiol (1985) (2002) 2.15
Heart failure and protein quality control. Circ Res (2006) 2.15
Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest (2007) 2.12
Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest (2010) 2.12
Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation (2006) 2.07
Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest (2013) 2.06
Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med (2002) 2.05
Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart. FASEB J (2006) 2.02
FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. J Biol Chem (2010) 2.00
Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol (2013) 1.99
Cardiac transgenic and gene transfer strategies converge to support an important role for troponin I in regulating relaxation in cardiac myocytes. Circ Res (2007) 1.95
Elevated Ca2+ sparklet activity during acute hyperglycemia and diabetes in cerebral arterial smooth muscle cells. Am J Physiol Cell Physiol (2009) 1.93
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. Cardiovasc Res (2010) 1.93
Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A (2007) 1.93
Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. J Biol Chem (2006) 1.92
Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature (2011) 1.91
Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A (2002) 1.88
Mechanisms underlying heterogeneous Ca2+ sparklet activity in arterial smooth muscle. J Gen Physiol (2006) 1.86
Unrestrained erythroblast development in Nix-/- mice reveals a mechanism for apoptotic modulation of erythropoiesis. Proc Natl Acad Sci U S A (2007) 1.86
Re-employment of developmental transcription factors in adult heart disease. Semin Cell Dev Biol (2006) 1.82
Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy. J Biol Chem (2004) 1.82
A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. J Mol Cell Cardiol (2011) 1.79
Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo. J Biol Chem (2005) 1.78
Ablation of ventricular myosin regulatory light chain phosphorylation in mice causes cardiac dysfunction in situ and affects neighboring myofilament protein phosphorylation. J Biol Chem (2008) 1.75
With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure. J Mol Cell Cardiol (2008) 1.74
Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation (2006) 1.73
Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J Mol Cell Cardiol (2009) 1.72
Mitochondrial dysfunction and apoptosis underlie the pathogenic process in alpha-B-crystallin desmin-related cardiomyopathy. Circulation (2005) 1.72
PKC-betaII sensitizes cardiac myofilaments to Ca2+ by phosphorylating troponin I on threonine-144. J Mol Cell Cardiol (2006) 1.71
Altered skeletal muscle phenotypes in calcineurin Aalpha and Abeta gene-targeted mice. Mol Cell Biol (2003) 1.71
Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol (2003) 1.69
MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation (2004) 1.69
TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc Natl Acad Sci U S A (2010) 1.66
Endoplasmic reticulum-mitochondria crosstalk in NIX-mediated murine cell death. J Clin Invest (2008) 1.65
Calcineurin regulates NFAT-dependent iNOS expression and protection of cardiomyocytes: co-operation with Src tyrosine kinase. Cardiovasc Res (2006) 1.64
Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol (2006) 1.64
A critical function for Ser-282 in cardiac Myosin binding protein-C phosphorylation and cardiac function. Circ Res (2011) 1.61